Valproic acid

Generic Name: Valproic acid

Brand Names: Depakene, Depakote, Epival

Drug Type: Small Molecule

Chemical Formula: C_₈H_₁₆O_₂

CAS Number: 99-66-1

Unique Ingredient Identifier: 614OI1Z5WI

Background: Valproic acid, or valproate, is an fatty acid derivative and anticonvulsant originally synthesized in 1881 by Beverly S. Burton. It enjoyed use as a popular organic solvent in industry and pharmaceutical manufacturing for nearly a century. In 1963, a serendipitous discovery was made by George Carraz during his investigations into the anticonvulsant effects o...

Indication: Indicated for:

1) Use as monotherapy or adjunctive therapy in the management of complex partial seizures and simple or complex absence seizures.

2) Adjunctive therapy in the management of multiple seizure types that include absence seizures.

3) Prophylaxis of migraine headaches.

4) Acute management of mania associated with bipolar disorder.
...

Associated Conditions: Bipolar Disorder (BD), Complex Partial Seizure Disorder, Depressive Episodes, Migraine, Petit Mal Epilepsy, Seizure, multiple types, Acute Manic episode

Associated Therapies: -

Clinical Trials

Phenobarbital Versus Valproate for Generalized Convulsive Status Epilepticus

Phase 2

Conditions: Generalized Convulsive Status Epilepticus

Interventions: Drug: Phenobarbital
Drug: Valproate

First Posted Date: 2017-01-20

Last Posted Date: 2019-07-09

Lead Sponsor: Xuanwu Hospital, Beijing

Target Recruit Count: 120

Registration Number: NCT03025906

Locations: 🇨🇳
Xuanwu Hospital, Beijing, Beijing, China
🇨🇳
Xijing Hospital, Shanxi, Xi'an, China
🇨🇳
Zhongshan Hospital, Xiamen University, Xiamen, Fujian, China

and more 3 locations

Levetiracetam Versus Sodium Valproate in Children With Refractory Generalized Convulsive Status Epilepticus

Phase 2

Completed

Conditions: Grand Mal Status Epilepticus

Interventions: Drug: Intravenous levetiracetam
Drug: Sodium valproate

First Posted Date: 2016-09-30

Last Posted Date: 2016-09-30

Lead Sponsor: Banaras Hindu University

Target Recruit Count: 80

Registration Number: NCT02920060

A Dose Ranging Pilot Study for Intracerebroventricular (ICV) Delivery of Valproate in Subjects With Temporal Seizures

Phase 1

Completed

Conditions: Epilepsy

Interventions: Drug: Valproate

First Posted Date: 2016-09-14

Last Posted Date: 2023-03-16

Lead Sponsor: Cerebral Therapeutics LLC

Target Recruit Count: 6

Registration Number: NCT02899611

Locations: 🇦🇺
St. Vincent Hospital, Melbourne, Victoria, Australia

Valproic Acid for Idiopathic Nephrotic Syndrome

Phase 2

Conditions: Focal Segmental Glomerulosclerosis
Minimal Change Disease
Idiopathic Nephrotic Syndrome

Interventions: Drug: Valproic Acid

First Posted Date: 2016-09-12

Last Posted Date: 2017-06-20

Lead Sponsor: Universitair Ziekenhuis Brussel

Target Recruit Count: 15

Registration Number: NCT02896270

Locations: 🇧🇪
UVC Brugmann, Brussels, Belgium
🇧🇪
University Hospital Brussels, Brussels, Belgium

Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies

Terminated

Conditions: Bipolar Disorder

First Posted Date: 2016-09-08

Last Posted Date: 2024-03-12

Lead Sponsor: University of New Mexico

Target Recruit Count: 1037352

Registration Number: NCT02893371

Locations: 🇺🇸
Christophe G Lambert, Albuquerque, New Mexico, United States

A Study to Evaluate the Safety and Tolerability of Valproic Acid in Trauma Patients(Part 2)

Phase 1

Terminated

Conditions: Shock,Hemorrhagic
Trauma

Interventions: Drug: Isotonic saline solution
Drug: Valproic Acid

First Posted Date: 2016-08-19

Last Posted Date: 2017-11-06

Lead Sponsor: Dr. Hasan Alam

Target Recruit Count: 1

Registration Number: NCT02872428

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
The University of Michigan, Ann Arbor, Michigan, United States

Cost- Effectiveness and Quality of Life Assessment in Mood Disorder

Phase 4

Completed

Conditions: Bipolar Disorder

Interventions: Drug: Lithium
Drug: Valproic Acid
Drug: Carbamazepine

First Posted Date: 2016-08-17

Last Posted Date: 2020-11-20

Lead Sponsor: Federal University of Rio Grande do Sul

Target Recruit Count: 107

Registration Number: NCT02870283

Valproic Acid With Methylprenisonlone for the Treatment of Acute GVHD

Phase 2

Conditions: Peripheral Blood Stem Cell Transplantation
aGVHD

Interventions: Drug: VPA

First Posted Date: 2016-07-28

Last Posted Date: 2016-08-01

Lead Sponsor: Shanghai Jiao Tong University School of Medicine

Target Recruit Count: 55

Registration Number: NCT02848105

Locations: 🇨🇳
Blood & Marrow Transplantation Center, RuiJin Hospital, Shanghai, Shanghai, China

Influence of Valproic Acid on Extinction-based Therapy in Patients With Fear of Spiders.

Phase 2

Completed

Conditions: Phobia, Specific

Interventions: Drug: Placebo
Drug: Valproic Acid
Behavioral: Fear reactivation
Behavioral: No fear reactivation

First Posted Date: 2016-06-03

Last Posted Date: 2018-10-02

Lead Sponsor: Prof. Dominique de Quervain, MD

Target Recruit Count: 100

Registration Number: NCT02789813

Locations: 🇨🇭
Psychiatric University Clinics, University Basel, Basel, Switzerland

Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma

Phase 1

Conditions: Nasopharyngeal Carcinoma

Interventions: Drug: Gemcitabine
Drug: Valproic acid
Drug: Valganciclovir

First Posted Date: 2016-05-04

Last Posted Date: 2016-05-16

Lead Sponsor: Chang Gung Memorial Hospital

Target Recruit Count: 18

Registration Number: NCT02761291

Locations: 🇨🇳
Chang-Gung Memorial Hospital, Linkou, Taoyuan, Taiwan

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy